Media

Explore our news section for company press releases, media coverage, upcoming events, and scientific presentations. Here you'll find the latest milestones, insights, and announcements as we advance our pipeline and expand our impact in cell therapies for cancer and autoimmune disease.

Any Year
MEDCITY NEWS
Induced Mesenchymal Stem Cells: A New Frontier in Ovarian Cancer TreatmentRead more
Induced Mesenchymal Stem Cells: A New Frontier in Ovarian Cancer Treatment
Sep 29, 2025
Induced Mesenchymal Stem Cells: A New Frontier in Ovarian Cancer Treatment
PULSE 2.0
Ernexa Therapeutics: Interview With President & CEO Sanjeev Luther About The Innovative Cell Therapy CompanyRead more
Ernexa Therapeutics: Interview With President & CEO Sanjeev Luther About The Innovative Cell Therapy Company
Sep 29, 2025
Ernexa Therapeutics: Interview With President & CEO Sanjeev Luther About The Innovative Cell Therapy Company
FIRSTWORD PHARMA
Press Release Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer ResearchRead more
Press Release Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research
Sep 17, 2025
Press Release Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research
CELL & GENE PODCAST
Engineering Off-the-Shelf Cell Therapies for Cancer & Autoimmune Disease with Ernexa Therapeutics' Sanjeev LutherRead more
Engineering Off-the-Shelf Cell Therapies for Cancer & Autoimmune Disease with Ernexa Therapeutics' Sanjeev Luther
Sep 11, 2025
Engineering Off-the-Shelf Cell Therapies for Cancer & Autoimmune Disease with Ernexa Therapeutics' Sanjeev Luther
CLINICAL LEADER
Rethinking Clinical Development In The Age Of Synthetic Cell TherapyRead more
Rethinking Clinical Development In The Age Of Synthetic Cell Therapy
Sep 5, 2025
Rethinking Clinical Development In The Age Of Synthetic Cell Therapy
PHARMACEUTICAL TECHNOLOGY
A new way forward in ovarian cancer: why synthetic iMSCs could change the paradigmRead more
A new way forward in ovarian cancer: why synthetic iMSCs could change the paradigm
Aug 13, 2025
A new way forward in ovarian cancer: why synthetic iMSCs could change the paradigm
CELL & GENE THERAPY REVIEW
MSCs RisingRead more
MSCs Rising
Jul 30, 2025
MSCs Rising
PRECEDENCE RESEARCH
Next-Gen Delivery Systems for Genetic Drug Market Driven by Viral and Non-Viral Vector InnovationRead more
Next-Gen Delivery Systems for Genetic Drug Market Driven by Viral and Non-Viral Vector Innovation
Jul 24, 2025
Next-Gen Delivery Systems for Genetic Drug Market Driven by Viral and Non-Viral Vector Innovation
FIERCE BIOTECH
ASCO: Ernexa's 'Trojan Horse' stem cell therapy shrinks ovarian tumors in miceRead more
ASCO: Ernexa's 'Trojan Horse' stem cell therapy shrinks ovarian tumors in mice
Jun 2, 2025
ASCO: Ernexa's 'Trojan Horse' stem cell therapy shrinks ovarian tumors in mice
BOSTON CAMBRIDGE BIOTECH NETWORKS
ASCO: Ernexa’s ‘Trojan Horse’ stem cell therapy shrinks ovarian tumors in miceRead more
ASCO: Ernexa’s ‘Trojan Horse’ stem cell therapy shrinks ovarian tumors in mice
Jun 2, 2025
ASCO: Ernexa’s ‘Trojan Horse’ stem cell therapy shrinks ovarian tumors in mice
3 of 4